Source:http://linkedlifedata.com/resource/pubmed/id/12767844
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2003-5-27
|
| pubmed:abstractText |
The emergence of multidrug-resistant (MDR) Acinetobacter baumannii poses a therapeutic problem. The aim of this study was to assess the risk factors for nosocomial MDR-A. baumannii bloodstream infection (BSI) and the efficacy of ampicillin-sulbactam (A/S) in its treatment. Of 94 nosocomial A. baumannii BSI during the year 2000, 54% involved MDR strains, 81% of which were genetically related. Various risk factors for MDR-A. baumannii were found, of which intensive-care unit admission and prior aminoglycoside therapy were independently associated with MDR-A. baumannii acquisition on multivariate analysis. Of MDR-A. baumannii BSI cases, 65% received A/S and 35% inadequate antibiotic therapy, whereas of 43 non-MDR cases, 86% were treated according to susceptibility and 14% inappropriately with antibiotics to which these organisms were resistant. Crude mortality was comparable in the adequately treated groups. Respective mortalities among patients treated adequately and inadequately were 41.4 and 91.7% (p<0.001). Among severely ill patients, A/S therapy significantly decreased the risk of death (P=0.02 OR=7.64). MDR-A. baumannii has become highly endemic in our institution. A/S appears to be one of the last effective and safe empirical resorts for treatment of MDR A. baumannii BSI.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0195-6701
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
54
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
32-8
|
| pubmed:dateRevised |
2005-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:12767844-Acinetobacter Infections,
pubmed-meshheading:12767844-Acinetobacter baumannii,
pubmed-meshheading:12767844-Aged,
pubmed-meshheading:12767844-Ampicillin,
pubmed-meshheading:12767844-Cross Infection,
pubmed-meshheading:12767844-DNA, Bacterial,
pubmed-meshheading:12767844-Drug Resistance, Multiple, Bacterial,
pubmed-meshheading:12767844-Drug Therapy, Combination,
pubmed-meshheading:12767844-Female,
pubmed-meshheading:12767844-Hospital Bed Capacity, 500 and over,
pubmed-meshheading:12767844-Humans,
pubmed-meshheading:12767844-Intensive Care Units,
pubmed-meshheading:12767844-Israel,
pubmed-meshheading:12767844-Male,
pubmed-meshheading:12767844-Medical Records,
pubmed-meshheading:12767844-Microbial Sensitivity Tests,
pubmed-meshheading:12767844-Middle Aged,
pubmed-meshheading:12767844-Outcome Assessment (Health Care),
pubmed-meshheading:12767844-Polymerase Chain Reaction,
pubmed-meshheading:12767844-Retrospective Studies,
pubmed-meshheading:12767844-Risk Factors,
pubmed-meshheading:12767844-Sulbactam
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment.
|
| pubmed:affiliation |
Infectious Disease Institute, Soroka University Medical Centre and the Faculty for Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
|
| pubmed:publicationType |
Journal Article
|